BREEZE 3 Trial Results Chill Depomed's Hot Flash Drug
By Catherine Shaffer
Monday, October 17, 2011
Disappointing top-line results from a third Phase III trial of Depomed Inc.'s Serada cast a shadow on the drug's prospects with the FDA. The trial studied frequency and severity of hot flash episodes in menopausal women after four weeks, 12 weeks and 24 weeks.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.